Biodesix to Report Third Quarter 2022 Financial Results on November 3, 2022
20 Ottobre 2022 - 12:00PM
Business Wire
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic
solutions company with a focus on lung disease, today announced
that it will release financial results for the third quarter ended
September 30, 2022 before the open of trading on Thursday, November
3. Biodesix’s management will host a conference call and webcast to
discuss its financial results and provide a general business update
at 8:00 a.m. Eastern Time on the same day.
Listeners can register for the webcast via this link. Analysts
wishing to participate in the question and answer session should
use this link. A replay of the webcast will be available via the
company’s investor website approximately two hours after the call’s
conclusion. Those who plan on participating are advised to join 15
minutes prior to the start time.
About Biodesix Biodesix is a leading data-driven
diagnostic solutions company with a focus in lung disease. The
Company develops diagnostic tests addressing important clinical
questions by combining multi-omics through the power of artificial
intelligence. Biodesix offers five Medicare-covered tests for
patients with lung diseases. The blood based Nodify Lung® nodule
risk assessment testing strategy, consisting of the Nodify XL2® and
the Nodify CDT® tests, evaluates the risk of malignancy in
incidental pulmonary nodules, enabling physicians to better triage
patients to the most appropriate course of action. The blood based
IQLung™ strategy for lung cancer patients integrates the GeneStrat®
ddPCR™ test, the GeneStrat NGS™ test and the VeriStrat® test to
support treatment decisions across all stages of lung cancer with
results in an unprecedented average of 36-72 hours, expediting time
to treatment. Biodesix also leverages the proprietary and advanced
Diagnostic Cortex® AI (Artificial Intelligence) platform, to
collaborate with many of the world’s leading biotechnology and
pharmaceutical companies to solve complex diagnostic challenges in
lung disease. For more information about Biodesix, visit
biodesix.com.
Note Regarding Forward-Looking Statements This press
release may contain forward-looking statements that involve
substantial risks and uncertainties for purposes of the safe harbor
provided by the Private Securities Litigation Reform Act of 1995.
All statements contained in this press release other than
statements of historical fact, are forward-looking statements. The
words “believe,” “may,” “will,” “estimate,” “continue,”
“anticipate,” “intend,” “plan,” “expect,” “predict,” “potential,”
“opportunity,” “goals,” or “should,” and similar expressions are
intended to identify forward-looking statements. Such statements
are based on management’s current expectations and involve risks
and uncertainties. Actual results and performance could differ
materially from those projected in the forward-looking statements
as a result of many factors. Biodesix has based these
forward-looking statements largely on its current expectations and
projections about future events and trends. These forward-looking
statements are subject to a number of risks, uncertainties, and
assumptions. Forward-looking statements may include information
concerning the impact of the COVID-19 pandemic on Biodesix and its
operations, it is possible or assumed future results of operations,
including descriptions of its revenues, profitability, outlook, and
overall business strategy. Forward-looking statements are
inherently subject to risks and uncertainties, some of which cannot
be predicted or quantified. The Company's ability to continue as a
going concern could cause actual results to differ materially from
those contemplated in this press release and additionally, other
factors that could cause actual results to differ materially from
those contemplated in this press release can be found in the Risk
Factors section of Biodesix’s most recent annual report on Form
10-K, filed March 14, 2022 or subsequent quarterly reports on Form
10-Q during 2022, if applicable. Biodesix undertakes no obligation
to revise or publicly release the results of any revision to such
forward-looking statements, except as required by law. Given these
risks and uncertainties, readers are cautioned not to place undue
reliance on such forward-looking statements. All forward-looking
statements are qualified in their entirety by this cautionary
statement.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221020005318/en/
Media: Kieran O’Kane kieran.okane@biodesix.com (206)
548-6159
Investors: Chris Brinzey chris.brinzey@westwicke.com
(339) 970-2843
Grafico Azioni Biodesix (NASDAQ:BDSX)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Biodesix (NASDAQ:BDSX)
Storico
Da Lug 2023 a Lug 2024